Moving The Needle: Continuous Processing For Enhanced Monoclonal Antibody Production

Although therapeutic monoclonal antibodies (mAbs) have been around for over 25 years, production of these essential biologics has only recently started to transition from traditional methods to advanced bioprocessing techniques. Newer bioprocessing technologies, such as continuous processing, have demonstrated the ability to increase production speeds while reducing costs.

In a recent webinar titled "Monoclonal Antibodies and Continuous Processing: A Case Study Examination," experts from Cytiva and Chugai Pharmaceutical, a Roche company, discussed their unique collaboration for the continuous processing of mAbs. The partnership led to the successful implementation of a semi-continuous pilot processing line, which enabled increased productivity and a smaller footprint.